RT Journal Article SR Electronic T1 Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with 89Zr-DS-8895a JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 974 OP 980 DO 10.2967/jnumed.115.169839 VO 57 IS 6 A1 Burvenich, Ingrid J.G. A1 Parakh, Sagun A1 Gan, Hui K. A1 Lee, Fook-Thean A1 Guo, Nancy A1 Rigopoulos, Angela A1 Lee, Sze-Ting A1 Gong, Sylvia A1 O’Keefe, Graeme J. A1 Tochon-Danguy, Henri A1 Kotsuma, Masakatsu A1 Hasegawa, Jun A1 Senaldi, Giorgio A1 Scott, Andrew M. YR 2016 UL http://jnm.snmjournals.org/content/57/6/974.abstract AB Subtype A2 of the erythropoietin-producing hepatocellular tyrosine kinase (EphA2) cell surface receptor is expressed in a range of epithelial cancers. This study evaluated the molecular imaging of EphA2 expression in vivo in mouse tumor models using SPECT/MR and PET/MR and a humanized anti-EphA2 antibody, DS-8895a. Methods: DS-8895a was labeled with 111In, 125I, and 89Zr and assessed for radiochemical purity, immunoreactivity (Lindmo analysis), antigen-binding affinity (Scatchard analysis), and serum stability in vitro. In vivo biodistribution, imaging, and pharmacokinetic studies were performed with SPECT/MR and PET/MR. A dose-escalation study was also performed to determine EphA2 receptor saturability through tissue and imaging quantitative analysis. Results: All conjugates demonstrated good serum stability and specific binding to EphA2-expressing cells in vitro. In vivo biodistribution studies showed high uptake of 111In-CHX-A″-DTPA-DS-8895a and 89Zr-Df-Bz-NCS-DS-8895a in EphA2-expressing xenograft models, with no specific uptake in normal tissues. In comparison, retention of 125I-DS-8895a in tumors was lower because of internalization of the radioconjugate and dehalogenation. These results were confirmed by SPECT/MR and PET/MR. EphA2 receptor saturation was observed at the 30 mg/kg dose. Conclusion: Molecular imaging of tumor uptake of DS-8895a allows noninvasive measurement of EphA2 expression in tumors in vivo and determination of receptor saturation. 89Zr-Df-Bz-NCS-DS-8895a is suited for human bioimaging trials on the basis of superior imaging characteristics and will inform DS-8895a dose assessment and patient response evaluation in clinical trials.